NCT01766024View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Healthy

Interventions

DRUG

Interferon beta-1a

Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.

Trial Locations (1)

194104

City Mariin Hospital, Saint Petersburg